APP-FUBINACA

APP-FUBINACA
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide;
CAS Number	1185282-03-4 ;
PubChem CID	58124515;
UNII	TW71LSK9DG;
CompTox Dashboard (EPA)	DTXSID501032568 ;
Chemical and physical data
Formula	C24H21FN4O2
Molar mass	416.456 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N[C@H](C(N)=O)CC1=CC=CC=C1)C2=NN(CC3=CC=C(F)C=C3)C4=C2C=CC=C4;
	InChI InChI=1S/C24H21FN4O2/c25-18-12-10-17(11-13-18)15-29-21-9-5-4-8-19(21)22(28-29)24(31)27-20(23(26)30)14-16-6-2-1-3-7-16/h1-13,20H,14-15H2,(H2,26,30)(H,27,31)/t20-/m0/s1; Key:TZXBEYFALIFOAG-FQEVSTJZSA-N;

APP-FUBINACA is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.^[1] Pharmacological testing showed APP-FUBINACA to have only moderate affinity for the CB₁ receptor, with a Ki of 708 nM, while its EC₅₀ was not tested.^[2] It contains a phenylalanine amino acid residue in its structure. ^[3]

Legality

Sweden's public health agency suggested to classify APP-FUBINACA as hazardous substance on March 24, 2015.^[4]

References

^ "APP-FUBINACA". Cayman Chemical. Retrieved 15 July 2015.
^ WO 2009106982, Buchler IP, Hayes MJ, Hedge SG, Hockerman SL, Jones DL, Kortum SW, Rico JG, Tenbrink RE, Wu KK, "Indazole derivatives", published 3 September 2009, assigned to Pfizer Inc
^ Evelyn, Alex. "HHC (Hexahydrocannabinol)". Retrieved 19 December 2021.
^ "Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. Retrieved 16 July 2015.
^ Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, et al. (December 2020). "in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA". ACS Chemical Neuroscience. 11 (24): 4434–4446. doi:10.1021/acschemneuro.0c00644. PMID 33253529. S2CID 227246346.

[1] "APP-FUBINACA". Cayman Chemical. Retrieved 15 July 2015.

[2] WO 2009106982, Buchler IP, Hayes MJ, Hedge SG, Hockerman SL, Jones DL, Kortum SW, Rico JG, Tenbrink RE, Wu KK, "Indazole derivatives", published 3 September 2009, assigned to Pfizer Inc

[3] Evelyn, Alex. "HHC (Hexahydrocannabinol)". Retrieved 19 December 2021.

[4] "Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. Retrieved 16 July 2015.

[5] Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, et al. (December 2020). "in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA". ACS Chemical Neuroscience. 11 (24): 4434–4446. doi:10.1021/acschemneuro.0c00644. PMID 33253529. S2CID 227246346.

[1]

[2]

[3]

[4]

[5]

Legality

See also

References